Homepage of the 4^th Fabisch-Symposium
for Cancer Research and Molecular Cell Biology revolving around
2nd TARGETED TUMOR THERAPIES

The symposium dealt with the development of non-carrier-based targeted tumor therapies and their clinical application, with special focus on target recognition, drug design and production, and innovative strategies for improvement.

Speakers:
01 April

Christopher Bachran	Arthur E. Frankel	Daniel Vallera	Dafne L. Müller	M. Serena Fabbrini	Ursula Elsässer-Beile
Marco Colombatti	Mehmet K. Tur	Winfried S. Wels	Hans Bäumler	Andrew Thorburn	Mark Sutherland

02 April

Walter A. Hall	Kuslima Shogen	Susanna Rybak	Jürgen Krauss	Thomas Schirrmann	Claudia De Lorenzo
Matthias Maak	Güliz Parmaksiz	Marcelo Calderon	Kenneth D. Bagshawe	P. Markus Deckert	Kerry Chester

03 April

Masanori Onda	Stefan Barth	Ansgar Santel	Hendrik Fuchs	Wijnand Helfrich	Elke Pogge
Alexander Weng	Michael Rosenblum	Horst Dürkop	Jochen Probst	Radostina Georgieva	Stephen H. Leppla

Main Topics:

• Generation and design of chimeric toxins
  including antibody / growth factor design, toxin selection and coupling, and protein production
• Directed enzyme prodrug therapy
  including antibody- and gene-directed prodrug therapy
• Targeted RNases
  including onconase, targeting of HER2, CD30 and others
• Innovative tools to improve targeted tumor therapies
  including mutations, antigen masking, humanized proteins, molecular adaptors, improved target recognition, gene transfer, RNA interference
• Targeted tumor therapies in clinical applications
  including all phases of clinical trials

Supported by the Fabisch-Stiftung and